Clinical Trial Update: Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 study of VELCADE (bortezomib) for injection in patients with light-chain (AL) amyloidosis has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Amyloidosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-08-13